Suva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011 Apr;7(4):208–218. [PMC free article: PMC3134309] [PubMed: 21200394]

Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s–6249s. [PubMed: 17062708]

^PrXgeva^® (denosumab) 120 mg/1.7 mL solution for injection single-use vial [product monograph]. Mississauga (ON): Amgen Canada Inc; Mar 31, 2015.

Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol [Internet]. Mar 20, 2011. [cited 2015 May 27]. pp. 1125–1132. Available from: http://jco​.ascopubs.org​/content/29/9/1125.full.pdf+html. [PubMed: 21343556]

Vadhan-Raj S, von Moos R, Fallowfield LJ, Patrick DL, Goldwasser F, Cleeland CS, et al. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol [Internet]. Dec, 2012. [cited 2015 Jul 2]. pp. 3045–3051. Available from: http://annonc​.oxfordjournals​.org/content/23/12/3045​.full.pdf+html. [PubMed: 22851406]

Ford J, Cummins E, Sharma P, Elders A, Stewart F, Johnston R, et al. Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. Health Technol Assess [Internet]. Jul, 2013. [cited 2015 Aug 31]. pp. 1–386. Available from: http://www​.ncbi.nlm.nih​.gov/books/NBK260765​/pdf/Bookshelf_NBK260765.pdf. [PMC free article: PMC4780939] [PubMed: 23870108]

Ford JA, Jones R, Elders A, Mulatero C, Royle P, Sharma P, et al. Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. Eur J Cancer. 2013 Jan;49(2):416–430. [PubMed: 22906748]

Clinical Study Report: 20050244. A randomized, double-blind, multicenter study of denosumab compared with zoledronic acid (Zometa^®) in the treatment of bone metastases in subjects with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. [Primary analysis]. [CONFIDENTIAL internal manufacturer's report]. Thousand Oaks (CA): Amgen Inc; Jan 26, 2010.

Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, et al. NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw. 2013 Aug;11 Suppl 3:S1–S50. [PubMed: 23997241]

Prefilled syringe or vial [product monograph]. Mississauga (ON): Amgen Canada Inc; Oct 20, 2014. ^PrProlia^® (denosumab) 60 mg/mL solution for injection.

^PrZometa^® concentrate (zoledronic acid for injection) 4 mg zoledronic acid/5 mL incorporated as the monohydrate for intravenous infusion [product monograph]. Dorval (QC): Novartis Pharmaceuticals Canada Inc; Dec 5, 2014.

^PrAredia^® (pamidronate disodium for injection) 30 mg, 90 mg for i.v. infusion only [product monograph]. Dorval (QC): Novartis Pharmaceuticals Canada Inc; Apr 17, 2014.

^PrBonefos^® clodronate disodium for injection 60 mg/mL for slow intravenous infusion only and clodronate disodium capsules 400 mg/capsule [product monograph]. Toronto: Bayer Inc.; Sep 22, 2011.

Atkinson TM, Rosenfeld BD, Sit L, Mendoza TR, Fruscione M, Lavene D, et al. Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI). J Pain Symptom Manage. 2011 Mar;41(3):558–565. [PMC free article: PMC3062715] [PubMed: 21131166]

Mathias SD, Crosby RD, Qian Y, Jiang Q, Dansey R, Chung K. Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form. J Support Oncol. 2011 Mar;9(2):72–78. [PubMed: 21542414]

Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993 Mar;11(3):570–579. [PubMed: 8445433]

Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002 May;11(3):207–221. [PubMed: 12074259]

Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70. [PMC free article: PMC2248572] [PubMed: 18154669]

Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005 Aug;14(6):1523–1532. [PubMed: 16110932]

Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res [Internet]. Feb 15, 2006. [cited 2015 May 26]. pp. 1221–1228. Available from: http:​//clincancerres​.aacrjournals.org/content/12/4/1221.long. [PubMed: 16489077]

Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005;(3):CD003474. [PubMed: 16034900]

von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, et al. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer. 2013 Dec;21(12):3497–3507. [PubMed: 23975226]

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012 Nov;48(16):3082–3092. [PubMed: 22975218]

Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014 Mar;22(3):679–687. [PubMed: 24162260]

Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012 Dec;7(12):1823–1829. [PubMed: 23154554]

Lipton A, Smith MR, Ellis GK, Goessl C. Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol [Internet]. 2012. [cited 2015 Jul 2]. pp. 287–303. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles​/PMC3427033/pdf/cmo-6-2012-287.pdf. [PMC free article: PMC3427033] [PubMed: 22933844]

Perez-Lopez FR. Effects of denosumab in patients with bone metastases from solid cancers. Climacteric. 2014;17(5):616–618.

Shapiro CL. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Breast Diseases. 2013;24(3):220–221. [PubMed: 22951813]

Lippuner K, Wolff JM, Hadji P, Braun A, Ke C, Steinle T, et al. Risk reduction for vertebral fractures in patients with normal to osteopenic bone mineral density receiving denosumab: a subgroup analysis of the HALT Prostate Cancer Trial. Osteologie. 2014;23(2):117–122.

Schmitz-Drager BJ, Weiss C, Ebert T, Dorsam J, Bismarck E. Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration. Urol Int. 2013;90(3):329–333. [PubMed: 23407093]

Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol [Internet]. Feb, 2015. [cited 2015 Jul 2]. pp. 368–374. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles​/PMC4304378/pdf/mdu519.pdf. [PMC free article: PMC4304378] [PubMed: 25425475]

Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015 Aug 1;386(9992):433–443. [PubMed: 26040499]

Diel IJ, Body JJ, Stopeck AT, Vadhan-Raj S, Spencer A, Steger G, et al. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Eur J Cancer. 2015 Jul;51(11):1467–1475. [PubMed: 25976743]

Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer [Internet]. Feb 15, 2013. [cited 2015 Jul 2]. pp. 832–838. Available from: http:​//onlinelibrary​.wiley.com/doi/10.1002/cncr.27789/epdf. [PubMed: 22951813]

Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res [Internet]. Sep 1, 2012. [cited 2015 Jul 2]. pp. 4841–4849. Available from: http:​//clincancerres​.aacrjournals.org/content/18/17/4841​.full.pdf+html. [PubMed: 22893628]

Chung KC, Barlev A, Braun AH, Qian Y, Zagari M. Assessing analgesic use in patients with advanced cancer: development of a new scale--the Analgesic Quantification Algorithm. Pain Med. 2014 Feb;15(2):225–232. [PubMed: 24400921]

Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994 Mar;23(2):129–138. [PubMed: 8080219]

Clinical Study Report: 20050136. A randomized, double-blind, multicenter study of denosumab compared with zoledronic acid (Zometa^®) in the treatment of bone metastases in subjects with advanced breast cancer. [Primary analysis]. [CONFIDENTIAL internal manufacturer's report]. Thousand Oaks (CA): Amgen Inc; Oct 29, 2009.

Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004 Sep;57(9):898–910. [PubMed: 15504633]

Pickard AS, Wilke CT, Lin HW, Lloyd A. Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics. 2007;25(5):365–384. [PubMed: 17488136]

Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003 Aug 15;21(16):3150–3157. [PubMed: 12915606]